Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya

BACKGROUND: In 2020, 14% of diagnosed persons living with HIV (PLWH) in Kenya were not taking antiretroviral therapy (ART), and 19% of those on ART had unsuppressed viral loads.

Long-acting antiretroviral therapy (LA-ART) may increase viral suppression by promoting ART uptake and adherence.

We conducted key informant (KI) interviews with HIV experts in Kenya to identify product and delivery attributes related to the acceptability and feasibility of providing LA-ART to PLWH in Kenya.

METHODS: Interviews were conducted via Zoom on potential LA-ART options including intra-muscular (IM) injections, subcutaneous (SC) injections, implants, and LA oral pills.

KI were asked to discuss the products they were most and least excited about, as well as barriers and facilitators to LA-ART roll-out.

In addition, they were asked about potential delivery locations for LA-ART products such as homes, pharmacies, and clinics.

Interviews were recorded and transcribed, and data were analyzed using a combination of inductive and deductive coding.

RESULTS: Twelve KI (5 women, 7 men) participated between December 2021 and February 2022.

Overall, participants reported that LA-ART would be acceptable and preferable to PLWH because of fatigue with daily oral pills.

They viewed IM injections and LA oral pills as the most exciting options to ease pill burden and improve adherence.

KI felt that populations who could benefit most were adolescents in boarding schools and stigmatized populations such as sex workers.

SC injections and implants were less favored, as they would require new training initiatives for patients or healthcare workers on administration.

In addition, SC injections would require refrigeration and needle disposal after use.

Some KI thought patients, especially men, might worry that IM injections and implants would impact fertility, given their role in family planning.

Pharmacies were perceived by most KI as suboptimal delivery locations; however, given ongoing work in Kenya to include pharmacies in antiretroviral delivery, they recommended asking patients their views.

CONCLUSION: There is interest and support for LA-ART in Kenya, especially IM injections and LA oral pills.

Identifying patient preferences for modes and delivery locations and addressing misconceptions about specific products as they become available will be important before wide-scale implementation.